By examining the anti-tumor potential of ANPs, we provided sufficient information that ANPs inhibit the conversion of GDP-RAS to GTP-RAS, the RAS-MEK1/2-ERK1/2 kinase cascade, and the RAS-MEK1/2-ERK1/2 kinase cascade cross-talk with VEGF, β-catenin, JNK, WNT, and STAT3. The gene discussed is MAP2K1; the disease is neoplasm.